Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib Adjuvant Therapy in FGFR2+ iCCA
NCT05565794Phase 2Terminated
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2022
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Institut für Klinische Krebsforschung. Started Nov 2022; status: terminated.
02
Drugs
pemigatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05565794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565794.